Clinical Trials
158 trialsA Study of Chemoradiotherapy With SHR-1316 For Treatment of Locally Advanced Cervical Cancer
Shanghai Shengdi Pharmaceutical Co., Ltd
RELEVENT
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Biomarker-oriented Study of Durvalumab (MEDI4736) in Combination With Olaparib and Paclitaxel in Gastric Cancer
Seoul National University Hospital
Atezolizumab Plus CArboplatin Plus Nab-paclitaxel
Consorzio Oncotech
Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor
University Health Network, Toronto
Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer
Fujian Cancer Hospital
FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma
Case Comprehensive Cancer Center
Adjuvant Sequential & Concurrent CarboTaxol + Radiotherapy for High Risk Endometrial Cancer
Loyola University
ALTER-G-001
Ruijin Hospital
MITO CERV 2
National Cancer Institute, Naples
A Phase II Trial of Neoadjuvant Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Chemoradiation
Icahn School of Medicine at Mount Sinai
MITO END-3
National Cancer Institute, Naples
Role of Curcumin in Paclitaxel Induced PN
Ain Shams University
InterAACT
Eastern Cooperative Oncology Group
Tislelizumab Combined With Chemotherapy in the Cross-line Treatment of First-line Resistant Advanced Gastric Cancer
Fujian Cancer Hospital
Trilaciclib Prior to Chemotherapy Plus Tislelizumab as 1L Treatment for Advanced Squamous Non-Small-Cell Lung Cancer
Sichuan University
Effect of Platinum-based Versus Non-platinum-based Neoadjuvant Chemotherapy in Triple-negative Breast Cancer
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Surgical Conversion of Candonilimab (AK104) Plus Paclitaxel, S-1 and Apatinib for Unresectable Advanced G/GEJ Cancer
Tianjin Medical University Cancer Institute and Hospital
Pembrolizumab Plus Paclitaxel, Cisplatin Followed by Surgery for Locally Advanced ESCC (KEYSTONE-001)
Tianjin Medical University Cancer Institute and Hospital
MITO28MaNGOov4
National Cancer Institute, Naples
Intraperitoneal Chemotherapy in Gastric Cancer With Peritoneal Carcinomatosis
Instituto do Cancer do Estado de São Paulo
Neoadjuvant Inetetamab Combined With Pertuzumab and Paclitaxel/Carboplatin for Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Chidamide Plus PD-1 Plus Paclitaxel of Neoadjuvant Treatment in Low HR Expression,HER2-negative Early Breast Cancer.
Sun Yat-sen University
A Phase II Study of Rulonilimab Combined With Chemotherapy in the First-Line Treatment for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Shandong New Time Pharmaceutical Co., LTD
Heated Intraperitoneal Chemotherapy in Primary Ovarian Cancer Patients
University of Kansas Medical Center
BREAKFAST
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
A Phase II Study Evaluating the Efficacy and Safety of Pembrolizumab in Combination With Chemotherapy as Neoadjuvant Therapy for Triple-negative Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
A Trial of Camrelizumab for Injection in Combination With Famitinib Malate Capsule and Paclitaxel For Injection(Albumin Bound) in Advanced Solid Tumors of Patients
Jiangsu HengRui Medicine Co., Ltd.
Carrelizumab Combined With Chemotherapy for Adjuvant Therapy of Esophageal Squamous Cell Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Conversion Therapy of Disitamab Vedotin Combined With Sintilimab and S-1 in HER2 Overexpression Gastric Cancer
Tianjin Medical University Cancer Institute and Hospital
FTANLCNDG
Qianfoshan Hospital
AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC
ChineseAMS
Neoadjuvant Therapy of Camrelizumab Combined With Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Correlation Between Efficacy of Osimertinib and EGFR T790M Status and Ratio Via ddPCR in NSCLC
Peking Union Medical College
Recombinant Human Angioendostatin /PD-1 Mab Combined With First-line Chemotherapy in the Treatment of Driver Gene Negative Advanced NSCLC
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer
Saitama Medical University International Medical Center
Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell Cancer
Zhejiang Cancer Hospital
Effect of Albumin-bound Paclitaxel Plus Carboplatin Compared With Paclitaxel Plus Carboplatin in Patients Receiving Neoadjuvant Chemotherapy for Advanced Ovarian, Fallopian Tube or Peritoneal Cancer: A Phase 2 Single Center Clinical Trial
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Donafenib for Recurrent Cervical Cancer
Peking Union Medical College Hospital
COPELIA
University of Manchester
WUHIPEC01
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Tislelizumab Combined With Chemotherapy in the Treatment of Bone Metastases of Unknown Primary
Shanghai Changzheng Hospital
Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced Squamous NSCLC With Brain Metastases
Sun Yat-sen University
Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors
GOG Foundation
Efficacy and Safety of Sintilimab Combined Intraperitoneal and Intravenous Paclitaxel Plus Oral S-1 in Gastric Cancer Patients With Peritoneal Metastasis
Ruijin Hospital
Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Fudan University
First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in Advanced Cervical Cancer
Sun Yat-sen University
Exploration of Immunodynamic Monitoring in the Population Evaluation of Neoadjuvant Chemotherapy Immunotherapy in Patients With Solid Tumors of the Chest.
Sichuan Cancer Hospital and Research Institute
MITO29
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
MITO CERV 3
Fondazione Policlinico Universitario Agostino Gemelli IRCCS